Form 4 for PCVX Vaxcyte, Inc.
Accepted 2023-10-16 00:00:00 ET · period of report 2023-10-12 · accession 0001209191-23-052850 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-16 | 2023-10-12 | PCVX | Wassil Jim | COO | M - OptEx | $2.42 | +5,000 | 175.9K | +3% | +$12.1K |
| D | 2023-10-16 | 2023-10-12 | PCVX | Wassil Jim | COO | M - OptEx | $0.00 | -5,000 | 102.6K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-12 | M | A | 5,000 | $2.42 | 175,935 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2023-10-12 | M | D | 5,000 | $0.00 | 102,555 | D | $2.42 · — to 2029-12-16 | 5,000 Common Stock | (F1) 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. |